Tim-3/galectin-9 pathway and mMDSC control primary and secondary resistances to PD-1 blockade in lung cancer patients.

Limagne, Emeric; Richard, Corentin; Thibaudin, Marion; Fumet, Jean-David; Truntzer, Caroline; Lagrange, Aurélie; Favier, Laure; Coudert, Bruno; Ghiringhelli, François

Limagne, Emeric; Richard, Corentin; Thibaudin, Marion; Fumet, Jean-David; Truntzer, Caroline; Lagrange, Aurélie; Favier, Laure; Coudert, Bruno; Ghiringhelli, François.

Afiliação

Limagne E; Platform of Transfer in Cancer Biology, Centre Georges-François Leclerc, Dijon, France.
Richard C; Platform of Transfer in Cancer Biology, Centre Georges-François Leclerc, Dijon, France.
Thibaudin M; Univ. Bourgogne Franche-Comté, Dijon, France.
Fumet JD; Platform of Transfer in Cancer Biology, Centre Georges-François Leclerc, Dijon, France.
Truntzer C; Platform of Transfer in Cancer Biology, Centre Georges-François Leclerc, Dijon, France.
Lagrange A; Department of Medical Oncology, Centre Georges-François Leclerc, Dijon, France.
Favier L; Platform of Transfer in Cancer Biology, Centre Georges-François Leclerc, Dijon, France.
Coudert B; Department of Medical Oncology, Centre Georges-François Leclerc, Dijon, France.
Ghiringhelli F; Department of Medical Oncology, Centre Georges-François Leclerc, Dijon, France.

Oncoimmunology ; 8(4): e1564505, 2019.

Article em En | MEDLINE | ID: mdl-30906658

Palavras-chave

Lung cancer; MDSC; Tim-3; anti-PD-1; immune checkpoint; nivolumab

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 1_ASSA2030 / 2_ODS3 Base de dados: MEDLINE Idioma: En Revista: Oncoimmunology Ano de publicação: 2019 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google